Answers are grounded in this paper and cite their sources.
To understand the real-world treatment switch rates of atogepant versus calcitonin gene-related peptide monoclonal antibodies (CGRP mAbs) using claims data from the United States.
No takes yet. Share an insight, caveat, or question.
Lipton et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: